利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.039 秒)

    METHODS FOR INHIBITION OF SCARRING
    1.
    发明申请
    METHODS FOR INHIBITION OF SCARRING 审中-公开
    抑制扫描的方法

    公开(公告)号：US20110166067A1

    公开(公告)日：2011-07-07

    申请号：US13003760

    申请日：2008-12-11

    申请人： Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Nicholas Goldspink ,  Kerry Nield ,  Abdul Sattar ,  James Bush

    发明人： Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Nicholas Goldspink ,  Kerry Nield ,  Abdul Sattar ,  James Bush

    IPC分类号： A61K38/18 ,  C07K14/495 ,  A61P17/02 ,  A61P9/00

    CPC分类号： A61K38/1841

    摘要： The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-β3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment TGF-β3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-β3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.

    摘要翻译： 本发明提供使用TGF-β3抑制人类瘢痕形成的新治疗方法，以及用于抑制人瘢痕形成的新用途的TGF-β3。 在治疗的第一次发生中，TGF-β1被提供给每个厘米的伤口边缘或每厘米的伤口以第一治疗有效量形成的部位; 并且在随后的治疗发生中，在更大的治疗有效量的TGF-βb中，向伤口边缘的每厘米提供TGF-β; 3。 治疗的发生发生在彼此之间8小时至48小时之间。 TGF-β可以通过皮内注射来提供。 还提供了选择用于抑制与人类伤口愈合相关的瘢痕形成的适当治疗方案的试剂盒和方法。

    MEDICAMENTS AND METHODS FOR INHIBITION OF NON-OCULAR SCARRING
    2.
    发明申请
    MEDICAMENTS AND METHODS FOR INHIBITION OF NON-OCULAR SCARRING 审中-公开
    用于抑制非眼科疾病的药物和方法

    公开(公告)号：US20100204248A1

    公开(公告)日：2010-08-12

    申请号：US12671005

    申请日：2008-07-31

    申请人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

    发明人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

    IPC分类号： A61K31/52 ,  C07D473/38 ,  A61P17/02

    CPC分类号： A61K31/407 ,  A61K31/52

    摘要： Provided is the use of an agonist of a member of the nuclear hormone receptor NR4A subgroup in the manufacture of a medicament for the prevention, reduction or inhibition of scarring in a non-ocular tissue. Also provided is a method of preventing, reducing or inhibiting scarring in a non-ocular tissue, the method comprising administering a therapeutically effective amount of an agonist of a member of the nuclear hormone receptor NR4A subgroup to a patient in need of such prevention, reduction or inhibition. The NR4A agonist may be 6-mercaptopurine. The medicaments and methods may preferably be used to prevent, reduce or inhibit scarring in the skin. The medicaments and methods of the invention may be used to accelerate healing of wounds.

    摘要翻译： 提供了核激素受体NR4A亚组的成员的激动剂在制备用于预防，减少或抑制非眼组织中的瘢痕形成的药物中的用途。 还提供了一种在非眼组织中预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，还原的患者施用治疗有效量的激素受体NR4A亚组成员的激动剂 或抑制。 NR4A激动剂可以是6-巯基嘌呤。 药物和方法可优选用于预防，减少或抑制皮肤中的瘢痕形成。 本发明的药物和方法可用于加速伤口愈合。

    Medicaments and Methods for Inhibition of Scarring
    4.
    发明申请
    Medicaments and Methods for Inhibition of Scarring 审中-公开
    药物和抑制疤痕的方法

    公开(公告)号：US20110082171A1

    公开(公告)日：2011-04-07

    申请号：US12995900

    申请日：2009-06-02

    申请人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nick Goldspink

    发明人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nick Goldspink

    IPC分类号： A61K31/437 ,  A61P17/02

    CPC分类号： A61K31/437

    摘要： Provided is the use of an agonist of a GABAA receptor for use in the prevention, reduction or inhibition of scarring formed on healing of a wound. Also provided is a method of preventing, reducing or inhibiting scarring formed on healing of a wound, in which a therapeutically effective amount of an agonist of a GABAA receptor is administered to a patient in need of such prevention, reduction or inhibition. The GABAA receptor agonist used may be an agonist specific to the GABAA receptor, such as Gaboxadol (7-tetra hydroisoxazolo[5,4-c]pyridin-3-ol), or a pharmaceutically acceptable salt thereof. The scarring to be prevented, reduced or inhibited may be scarring formed on healing of a wound of the dermis.

    摘要翻译： 提供了用于预防，减少或抑制伤口愈合时形成的瘢痕形成的GABA A受体激动剂的用途。 还提供了预防，减少或抑制伤口愈合时形成的瘢痕形成的方法，其中向需要这种预防，减少或抑制的患者施用治疗有效量的GABA A受体激动剂。 所使用的GABA A受体激动剂可以是对GABA A受体特异的激动剂，例如加波沙朵（7-四氢异恶唑并[5,4-c]吡啶-3-醇））或其药学上可接受的盐。 要防止，减少或抑制的疤痕可能在真皮的伤口愈合时形成瘢痕。

    WNT3A FOR INHIBITION OF SCARRING
    5.
    发明申请
    WNT3A FOR INHIBITION OF SCARRING 审中-公开
    WNT3A用于抑制扫描

    公开(公告)号：US20110212897A1

    公开(公告)日：2011-09-01

    申请号：US12527182

    申请日：2008-02-14

    申请人： Mark William James Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    发明人： Mark William James Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    IPC分类号： C07K14/435 ,  A61K38/17 ,  A61P17/02

    CPC分类号： A61K38/1709

    摘要： Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT3A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition. The methods and medicaments of the invention are suitable for use in the prevention, reduction or inhibition of scarring arising as a result of healing of a wound, or scarring associated with a fibrotic disorder. The methods and medicaments disclosed are of particular use in preventing, reducing or inhibiting scarring of the skin.

    摘要翻译： 提供用作预防，减少或抑制瘢痕形成的药物的WNT3A或其治疗有效的片段或衍生物。 还提供了预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，减少或抑制的患者施用治疗有效量的WNT3A或其治疗有效的片段或衍生物。 本发明的方法和药物适用于预防，减少或抑制由于伤口愈合或与纤维化病症相关的瘢痕形成引起的瘢痕形成。 所公开的方法和药物特别用于预防，减少或抑制皮肤瘢痕形成。

    METHODS FOR THE INHIBITION OF SCARRING
    10.
    发明申请
    METHODS FOR THE INHIBITION OF SCARRING 审中-公开
    抑制扫描的方法

    公开(公告)号：US20110152189A1

    公开(公告)日：2011-06-23

    申请号：US13003755

    申请日：2008-12-11

    申请人： Mark William James Ferguson ,  Sharon O'Kane ,  Tracey Mason ,  Mark Cooper ,  Nick Occleston ,  David Fairlamb ,  James Bush

    发明人： Mark William James Ferguson ,  Sharon O'Kane ,  Tracey Mason ,  Mark Cooper ,  Nick Occleston ,  David Fairlamb ,  James Bush

    IPC分类号： A61K38/18 ,  A61P17/02

    CPC分类号： A61K38/1841 ,  A61K9/0019 ,  A61K9/0021 ,  A61K38/00

    摘要： The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350 ng and 1000 ng of TGF-β3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350 ng and 1000 ng of TGF-β3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-β3 provided may be the same in each incidence of treatment. The amount of TGF-β3 provided per centimetre in each incidence of treatment may preferably be approximately 500 ng. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.

    摘要翻译： 本发明提供使用TGF-β3抑制人类瘢痕形成的新治疗方法，以及用于抑制人瘢痕形成的新用途的TGF-β3。 在第一次治疗发生率中，每厘米的伤口边缘或要形成伤口的部位的每厘米处提供约350ng至1000ng的TGF-β1; 并且在第一次治疗发生后，在伤口形成之后发生，并且在第一次治疗后8至48小时之间，所述伤口被提供有大约350ng和1000ng之间的TGF-和bgr 3 伤口边缘的厘米，其中瘢痕形成被抑制。 所提供的TGF-β1的量可以在每次治疗发生率中相同。 在每次治疗发生率中每厘米提供的TGF-β1,3的量优选为约500ng。 TGF-β可以通过皮内注射来提供。 还提供了选择用于抑制与人类伤口愈合相关的瘢痕形成的适当治疗方案的试剂盒和方法。